ArticleJournal of inflammation research2025
Identification of Core SASP-Related Genes TGFBI and ANXA6 for Diagnosing Ulcerative Colitis-Related Colorectal Cancer Through Machine Learning.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore the role of senescence-associated secretory phenotype (SASP) in ulcerative colitis-related colorectal cancer (UCRCC) precision diagnosis and pathogenesis. Methods: In this study, we first screened the SASP-related genes (SASPRGs) in the ulcerative colitis (UC) and colorectal cancer (CRC) datasets using differentially expressed genes (DEGs) and weighted gene co-expression network analysis (WGCNA). Subsequently, the core SASPRGs were further identified using 113 combinations of 10 machine learning algorithms, and evaluating their expression levels, diagnostic efficacy, prognostic value, and relationship with immune cells. Expression patterns of core SASPRGs were analyzed using scRNA-seq, and a molecular regulatory network was constructed. In addition, immunotherapy response and drug sensitivity analysis were conducted to screen therapeutic drugs targeting core SASPRGs. Finally, their expression levels were validated through in vivo experiments. Results: We identified 12 core SASPRGs, among which TGFBI and ANXA6 exhibited satisfactory diagnostic efficacy and prognostic value for UC and CRC. ANXA6 and TGFBI are highly expressed in monocytes and fibroblasts, and are associated with the infiltration of multiple immune cells. In addition, high TGFBI and ANXA6 groups showed poor responses to immunotherapy. The candidate therapeutic drugs screened by drug sensitivity analysis showed good binding ability with ANXA6 and TGFBI. Finally, the expression levels of TGFBI and ANXA6 were significantly increased in UC and CRC mouse models. Conclusion: Overall, TGFBI and ANXA6 are crucial in UCRCC, serving as novel diagnostic markers. They exhibit robust predictive capabilities on patient prognosis and immunotherapy response, offering actionable insights to optimize therapeutic decision-making and advance personalized treatment paradigms in UCRCC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.